Table 3.
Molecular Profiles
| Patient No. | Hepatitis Status |
Mutational Profiling |
Immunohistochemistry | Best Tumor Response |
||
|---|---|---|---|---|---|---|
| p-Akt | p-mTOR | p-RPS6 | ||||
| 5 | HCV | NMI | Mod | Low | High | SD |
| 9 | HBV | NMI | Mod | Low | Low | PD |
| 11 | Negative | NMI | Low | Low | Mod | SD |
| 14 | HCV | NMI | Mod | Mod | High | PR |
| 18 | Negative | CTNNB1 (G34E) | Mod | Mod | High | SD |
| 22 | Negative | NMI | Low | Low | Low | SD |
| 23 | HBV | NMI | Mod | Low | Mod | PD |
| 24 | Negative | NMI | Low | Low | Mod | PD |
| 25 | HCV | NMI | ND | ND | ND | PD |
| 26 | Steatohepatitis | NMI | High | High | High | SD |
| 28 | Negative | NMI | Mod | Low | Mod | SD |
HBV indicates hepatitis B virus; HCV, hepatitis C virus; Mod, moderate; ND, not determined; NMI, no mutation identified; p-Akt, phosphorylated Akt; p-mTOR, phosphorylated mammalian target of rapamycin; p-RPS6, phosphorylated ribosomal protein S6 kinase; PD, progressive disease; PR, partial response; SD, stable disease.